Jazz Pharmaceuticals' IPO: Taking Stock of VC Dilution

The stockholder breakdown in Jazz Pharmaceuticals demonstrates how the company's founding VCs were significantly diluted by that company's massive Series B in 2004. As the company prepares for IPO it's worth considering how Ikaria Holdings' backers last month pulled in private equity support and managed to maintain their stakes in the company.

When Jazz Pharmaceuticals Inc. took in $250 million in Series B money back in 2004, it set itself up nicely to in-license the products and technology it needed to build its business. [See Deal] The fundraising was the biggest Series B round ever and represented the debut of Kohlberg Kravis Roberts & Co.—best known for mega-leveraged-buy-outs (LBOs)--in the very un-leveraged world of biopharmaceuticals. (See "Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level," START-UP, April 2004 Also see "Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level" - Scrip, 1 April, 2004..)

But mostly lost in all the musical puns and superlatives was the impact private equity dollars had on Jazz’s VCs....

More from Strategy

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

More from Business